Chiasma Inc.

75 articles with Chiasma Inc.

• Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings

  6/28/2021

  The Company’s annual report for the 12 months ended 31 December 2020, will be posted to shareholders in the coming days, along with a notice of general meeting.

• Chiasma Announces Submission of Marketing Authorization Application for MYCAPSSA® to the European Medicines AgencySubmission supported by previously announced data from Phase 3 MPOWERED™ study

  6/28/2021

  Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval of MYCAPSSA

• Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial

  5/27/2021

  Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to MYCAPSSA ® .

• Chiasma to Present Encore and New Data from MPOWERED™ Phase 3 Trial at Upcoming e-ECE and AACE Virtual Conferences

  5/20/2021

  Chiasma, Inc. announced that it will virtually present encore data from its MPOWERED™ Phase 3 clinical trial at the 23rd European Congress of Endocrinology and new data from the MPOWERED trial at the 30th Annual American Association of Clinical Endocrinology Meeting.

• 

  Biopharma Execs Address the Challenges of a Post-Pandemic Workplace

  5/18/2021

  If these companies are any indication, it appears that the biopharma industry will be a hybrid of virtual and physical workforces, and with this comes a whole new set of risks.

• Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt

  5/5/2021

  Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced financial results for the first quarter ended March 31, 2021

• 

  Amryt and Chiasma Combine to Form Rare and Orphan Diseases Powerhouse

  5/5/2021

  Amryt inked an all-stock acquisition deal with Chiasma. The combined company will focus on rare and orphan diseases with three marketed products and a strong development pipeline.

• Chiasma to Report First Quarter Financial Results on May 6, 2021

  4/29/2021

  Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, May 6, 2021 at 5:00 pm Eastern Time to discuss financial results for the quarter ended March 31, 2021 and to provide a business update.

• 

  Clinical Catch-Up: March 22-26

  3/29/2021

  There was a fair amount of clinical trial news last week. Here’s a look.

• Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021

  3/22/2021

  Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent phased launch of MYCAPSSA®

• Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021

  3/20/2021

  Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after switching from iSRLs

• Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021

  3/10/2021

  Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent approval of MYCAPSSA as the first and only oral therapy for the treatment of acromegaly

• Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

  3/4/2021

  Chiasma, Inc., a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its recent initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, announced financial results for the fourth quarter and year ended December 31, 2020 and provided a business update.

• Chiasma to Participate in the H.C. Wainwright Global Life Sciences Conference

  3/2/2021

  Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company, today announced that management will present a company overview at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9 th - Wednesday, March 10 th , 2021.

• 

  BioSpace Movers & Shakers, Jan. 22

  1/22/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Chiasma Announces Hiring of John Doyle as Chief Financial OfficerAppointment provides extensive commercial-stage public company financial leadership experience

  1/19/2021

  Chiasma, Inc. announced the hiring of John Doyle as its new Chief Financial Officer

• Chiasma Provides Corporate Update and Previews Expected 2021 Milestones

  1/6/2021

  MYCAPSSA®EMA submission for EU marketing approval on track for mid-2021 following positive results of MPOWERED Phase 3 clinical trial

• Chiasma to Participate in Two Investor Conferences in December

  11/23/2020

  Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be presenting and participating in investor meetings at both the Piper Sandler Healthcare Conference as well as the Evercore ISI HealthCONx Conference. Details

• Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results

  11/20/2020

  Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that it will host an expert panel on acromegaly and the results from its recently completed MPOWERED® Phase 3 clinical trial on Monday, November 30, 2020 at 11:00 am Eastern Time.

• Chiasma Announces Positive Topline Results from the MPOWERED™ Phase 3 Clinical Trial Comparing MYCAPSSA® (octreotide capsules) to Long Acting Injectables for the Maintenance Treatment of Adults with Acromegaly

  11/18/2020

  91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized, controlledphaseof the non-inferiority trial